...
首页> 外文期刊>Progress in Biophysics and Molecular Biology: An International Review Journal >Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
【24h】

Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.

机译:使用基于集成系统的心脏计算机模型对药物化合物进行临床前心脏安全性评估。

获取原文
获取原文并翻译 | 示例
           

摘要

Blockade of the delayed rectifier potassium channel current, I(Kr), has been associated with drug-induced QT prolongation in the electrocardiogram and life-threatening cardiac arrhythmias. However, it is increasingly clear that compound-induced interactions with multiple cardiac ion channels may significantly affect QT prolongation that would result from inhibition of only I(Kr) [Redfern, W.S., Carlsson, L., et al., 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58(1), 32-45]. Such an assessment may not be feasible in vitro, due to multi-factorial processes that are also time-dependent and highly non-linear. Limited preclinical data, I(Kr) hERG assay and canine Purkinje fiber (PF) action potentials (APs) [Gintant, G.A., Limberis, J.T., McDermott, J.S., Wegner, C.D., Cox, B.F., 2001. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 37(5), 607-618], were used for two test compounds in a systems-based modeling platform of cardiac electrophysiology [Muzikant, A.L., Penland, R.C., 2002. Models for profiling the potential QT prolongation risk of drugs. Curr. Opin. Drug. Discov. Dev. 5(1), 127-35] to: (i) convert a canine myocyte model to a PF model by training functional current parameters to the AP data; (ii) reverse engineer the compounds' effects on five channel currents other than I(Kr), predicting significant IC(50) values for [Formula: see text] and [Formula: see text] , which were subsequently experimentally validated; (iii) use the predicted ( [Formula: see text] and [Formula: see text] ) and measured (I(Kr)) IC(50) values to simulate dose-dependent effects of the compounds on APs in endocardial, mid-myocardial, and epicardiac ventricular cells; and (iv) integrate the three types of cellular responses into a tissue-level spatial model, which quantifiably predicted no potential for the test compounds to induce either QT prolongation or increased transmural dispersion of repolarization in a dose-dependent and reverse rate-dependent fashion, despite their inhibition of I(Kr) in vitro.
机译:延迟整流钾离子通道电流I(Kr)的阻滞与心电图中药物诱导的QT延长和危及生命的心律不齐有关。然而,越来越明显的是,化合物诱导的与多个心脏离子通道的相互作用可能会显着影响QT延长,这是由于仅抑制I(Kr)引起的[Redfern,WS,Carlsson,L.,et al。,2003。临床前心脏电生理学,临床QT间隔延长和扭转性扭转运动为多种药物指明了目标:在药物开发中具有暂时性安全裕度的证据。心血管Res。 58(1),32-45]。由于多因素过程也是时间相关的并且是高度非线性的,因此这种评估在体外可能不可行。有限的临床前数据,I(Kr)hERG分析和犬浦肯野纤维(PF)动作电位(APs)[Gintant,GA,Limberis,JT,McDermott,JS,Wegner,CD,Cox,BF,2001年。犬浦肯野纤维:获得性长QT综合征和药物引起的心律失常的体外模型系统。 J.心血管Pharmacol。 37(5),607-618]在基于系统的心脏电生理学建模平台中用于两种测试化合物[Muzikant,A.L.,Penland,R.C.,2002。用于分析潜在QT延长药物风险的模型。 Curr。 in药品。 Discov。开发人员5(1),127-35]到:(i)通过训练功能性当前参数到AP数据将犬肌细胞模型转换为PF模型; (ii)逆向工程化化合物对I(Kr)以外的五个通道电流的影响,预测[公式:参见文本]和[公式:参见文本]的有效IC(50)值,随后对它们进行了实验验证; (iii)使用预测的[公式]和[公式]以及测量的(I(Kr))IC(50)值来模拟化合物对心内膜中段AP的剂量依赖性作用心肌和心外膜心室细胞; (iv)将三种类型的细胞反应整合到组织水平的空间模型中,该模型可量化地预测测试化合物无可能以剂量依赖性和逆速率依赖性方式诱导QT延长或复极化的透壁分散增加,尽管它们在体外抑制了I(Kr)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号